Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site

被引:47
作者
Griffith, ME
Coulthart, A
Pemberton, S
George, AJT
Pusey, CD
机构
[1] Hammersmith Hosp, Imperial Coll Sch Med, Dept Haematol,Div Med, Renal Sect, London W12 0NN, England
[2] Hammersmith Hosp, Imperial Coll Sch Med, Dept Immunol, London W12 0NN, England
关键词
anti-neutrophil cytoplasmic antibodies; proteinase; 3; autoimmunity; epitopes; autoantibodies;
D O I
10.1046/j.1365-2249.2001.01420.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
ANCA with specificity for proteinase 3 (PR3), a neutrophil primary granule enzyme, are of diagnostic value in Wegener's granulomatosis (WG) and certain other forms of systemic vasculitis. There is evidence to suggest that they play a pathogenic role in disease, and that the interaction of ANCA with PR3 is likely to be important. We showed, using a resonant mirror biosensor, that C-ANCA from different patients recognized the same or closely related epitopes on PR3. Studies using linear peptides in the SPOT system confirmed the highly restricted nature of this interaction and identified five linear epitopes. Fluid-phase inhibition studies, using a different set of peptides, validated the sequences involved. Using a computer-generated model of the structure of PR3, four of five epitopes were shown to be intimately linked with the catalytic site. The restricted number of epitopes, and their location at the catalytic site, has important implications for the role of C-ANCA in the pathogenesis of vasculitis.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 44 条
[31]   REAL-TIME ANALYSIS OF ANTIBODY ANTIGEN REACTION-KINETICS [J].
MALMBORG, AC ;
MICHAELSSON, A ;
OHLIN, M ;
JANSSON, B ;
BORREBAECK, CAK .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1992, 35 (06) :643-650
[32]   Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1) [J].
Mayet, WJ ;
Schwarting, A ;
Orth, T ;
Duchmann, R ;
zumBuschenfelde, KHM .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 103 (02) :259-267
[33]  
MAYET WJ, 1993, CLIN EXP IMMUNOL, V94, P440
[34]  
PUSEY CD, 1987, LAB INVEST, V56, P23
[35]  
ROSSI F, 1991, CLIN EXP IMMUNOL, V83, P298
[36]  
SAVAGE COS, 1992, AM J PATHOL, V141, P335
[37]  
SAVAGE COS, 1993, EXP NEPHROL, V1, P190
[38]  
SOMMARIN Y, 1995, EXP NEPHROL, V3, P249
[39]  
Taekema-Roelvink MEJ, 1998, SCAND J IMMUNOL, V48, P37
[40]  
VAGDAMA P, 1992, ANALYST, V117, P1657